Robert Zivadinov MD, PhD

Robert Zivadinov

Robert Zivadinov
MD, PhD

Professor of Neurology and Professor of Biomedical Informatics

Department of Neurology

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Alzheimer Disease / Memory Disorders; Bioinformatics; Developmental Neurology; General Neurology; Multiple Sclerosis; Neurodegenerative disorders; Neuroimaging; Neuroimaging Analysis; Neurology; Neuroradiology - Radiology; Parkinson's; Vascular and Interventional Radiology

Contact Information
Buffalo Neuroimaging Analysis Center
D-2 Buffalo General Hospital
100 High St
Buffalo, New York 14203
Phone: (716) 859-7040
Fax: (716) 859-7066
rz4@buffalo.edu



Professional Summary:

I direct the Buffalo Neuroimaging Analysis Center (BNAC) and have established the center as a world leader in performing quantitative MRI analysis in neurodegenerative disorders. I also direct the Translational Imaging Center at UB’s Clinical Translational Research Center (CTRC). I strive to extend the boundaries of current knowledge about neurological diseases and disorders through innovative imaging research techniques and the application of bioinformatics resources. My efforts are directed toward advancing technical, basic and translational research at UB which will, in turn, advance patient care.

I have secured more than $30 million in research grants for collaborative research projects involving UB investigators as well as national and international collaborators. My research interests include structural and functional quantitative MRI analysis for humans and animals, including lesion/tumor identification and segmentation; perfusion and dynamic contrast-enhanced (DCE) mapping and quantification; fluid flow quantification; functional MRI analysis; diffusion tensor reconstruction and tractography; voxel-wise mapping and image-based group statistical analysis; longitudinal change analysis and tissue/pathology/structure volumetry. I study the application of these techniques in healthy individuals and in patients with various disease states such as multiple sclerosis (MS), stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, systemic lupus erythematosus and traumatic brain injury. I also concentrate on therapeutic interventions, including therapy directed toward assessing neuroprotective efforts in neurodegenerative disorders as well as the venous function, genetic and neuroepidemiology fields of these diseases.

I direct the neurology resident research program. Over a period of two years, I guide third- and fourth-year medical residents through a rigorous assigned scientific research project that is a critical, required part of their training. In addition, I mentor and supervise undergraduate, master’s and doctoral students and MRI fellows. In this role, I help to educate these trainees on clinical MRI use as well as neuroimaging analysis. I also oversee students and fellows conducting research in neurological disorders. One of the most rewarding experiences in my career is helping young physicians and researchers start successful clinical or research careers.

Education and Training:

  • PhD, University of Rijeka (2002)
  • University of Trieste (1999)
  • MD, University of Trieste (1995)
  • MS, University of Rijeka (1995)
  • MD, University of Rijeka (1993)

Employment:

  • Professor of Biomedical Informatics, Department of Biomedical Informatics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York (2018-present)
  • Director, Translational Imaging Center, Clinical Translational Research Center Jacobs School of Medicine & Biomedical Sciences (2017-present)
  • Steering Committee Member, Clinical Translational Research Award, Clinical Translational Research Center Jacobs School of Medicine & Biomedical Sciences (2017-present)
  • Director, MR Imaging, CTRC, CTRC, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2013-present)
  • Professor of Neurology, Neurology, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2011-present)
  • Clinical Professor of Neurology, Neurology, Florida International University College of Medicine (2009-present)
  • Director of Residency Research and Fellowship Training Program, University at Buffalo (2004-present)
  • Director of Buffalo Neuroimaging Analysis Center, Jacobs Neurological Institute (2003-present)
  • Scientific Consultant, National and International pharmaceutical industry and foundations (1999-present)

Awards and Honors:

  • Treasurer (2021)
  • 2019 Radiology Editor’s Recognition Award for Reviewing with Distinction (2019)
  • Exceptional Scholar (2018)
  • Golden Award (2018)
  • Richard C. Knudsen Publication Award (2017)
  • Silver Award of International Society for Neurovascular Disease (2016)
  • Fellow of American Neurological Association (2015)
  • Fellow of European Academy of Neurology (2015)
  • American Academy of Neurology Fellow (2010)
  • MS Community Champion Award (2010)
  • Biography included in the 21st ed. of Century Award for Achievement (2005)
  • Who's Who in Science and Engineering (2003)
  • Young Scientific Investigator Travel Award (2002)
  • Young Scientific Investigator Travel Award (2002)
  • First place for best Poster in Neuroimmunology (2001)
  • Young Scientific Investigator Travel Award (2001)
  • Second place for best Oral Communication (2000)

Research Expertise:

  • Neuroimaging

Research Centers:

  • Buffalo Neuroimaging Analysis Center
  • Clinical and Translational Research Center (CTRC)
  • Jacobs Neurological Institute

Grants and Sponsored Research:

  • April 2016–December 2021
    Physiological mechanisms of a biomarker of recovery from concussion.
    National Institute of Health.
    Role: Co-Investigator
  • October 2015–October 2020
    Delay discounting as a target for self-regulation in prediabetes.
    National Institute of Health.
    Role: Co-Investigator
  • June 2017–June 2020
    The effects of working memory training on brain function, structure, and cognition in MS
    National Multiple Sclerosis Society
    Role: Co-Investigator
    $622,839
  • August 2015–March 2019
    CTSA hub - Buffalo Clinical and Translational Research Center
    NIH/ NCATS
    Role: Contributor
  • July 2016–July 2018
    Cholesterol Biomarkers and Oxysterols in Multiple Sclerosis Progression
    NINDS
    Role: Co-Investigator
  • June 2013–December 2017
    Open-label, single-blinded, observational, prospective, 24-month, longitudinal, controlled study to assess the efficacy of fingolimod (Gilenya) on development of thalamus pathology and cognitive impairment in patients with RRMS
    Novartis, Inc.
    Role: Principal Investigator
  • June 2013–December 2017
    An open-label, prospective, observational, single-blinded,longitudinal, cross-over study to evaluate the effect of switching from daily injections of 20 mg glatiramer acetate (GA) to 40mg GA three times per week on thalamic path. in subjects with RRMS.
    TEVA Pharmaceuticals, Inc.
    Role: Principal Investigator
  • December 2014–December 2016
    Effect of teriflunomide (Aubagio) on cortico-basal ganglionic thalamo cortical gray matter connectivity in the Theiler's Murine Encephalomyelitis Virus model of demyelination.
    Genzyme, Inc.
    Role: Principal Investigator
  • October 2014–December 2016
    Do higher vitamin A levels improve disease severity progression in relapsing, remitting patients on either glatiramer acetate or interferono-beta disease modifying therapies and normal vitamin D levels.
    Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Role: Co-Investigator
  • June 2014–December 2016
    Intra-arterial Vaospasm trial; A multi-center prospective randomized study.
    The University of Texas Health Science Center at Houston
    Role: Co-Principal Investigator
  • May 2014–December 2016
    MRI services for double-blind, randomized, parallel-group, multicenter study comparing safety and efficacy of monotherapy with INT131 1 mg or 3 mg administered orally or placebo once daily in treatment naive patients with relapsing/remitting MS.
    Intekrin
    Role: Co-Principal Investigator
  • April 2014–December 2016
    MRI services for Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL study
    Claret Medical
    Role: Principal Investigator
  • December 2013–December 2016
    Defining the hierarchy of the anatomic, physiologic, and metabolic neuro-degenerative changes in optic neuritis and multiple sclerosis
    Neuro-Ophthalmologic Associates, PC.
    Role: Co-Principal Investigator
  • October 2013–December 2016
    Hyperbaric Oxygen therapy for Multiple Sclerosis Relapse.
    SUNY Stony Brook
    Role: Co-Investigator
  • March 2013–December 2016
    Lipoprotein and lipid metabolism in multiple sclerosis disease progression
    National Multiple Sclerosis Society
    Role: Principal Investigator
  • September 2014–December 2015
    Effect of teriflunomide (Aubagio) on the prevention of gray matter of gray matter atrophy progression in clinically isolated syndrome patients. The post-hoc, blinded MRI analysis of TOPIC study using advanced MRI assessments.
    Genzyme, Inc.
    Role: Co-Principal Investigator
  • August 2014–December 2015
    NeuroSTREAM - Neurological Software Tool for Reliable Atrophy Measurement
    Novartis, Inc.
    Role: Co-Principal Investigator
  • December 2013–December 2015
    A prospective, observational, single-blinded, longitudinal optical coherence tomography study of the effect of glatiramer acetate on retinal nerve fiber layer thickness in patients with relapsing-remitting multiple sclerosis over 24 months.
    TEVA Pharmaceuticals, Inc.
    Role: Principal Investigator
  • November 2013–December 2015
    MRI analysis of the brain damage occurring with the use of a cerebral protection system in patients undergoing trans-femoral aortic valve implantation.
    Claret Medical
    Role: Co-Principal Investigator
  • June 2013–December 2015
    The effect of teriflunomide (Aubagio) on gray matter pathology in multiple sclerosis; A 12-month prospective, observational, single-blinded, longitudinal study.
    Genzyme, Inc.
    Role: Principal Investigator
  • May 2012–December 2015
    Open-label, single-blinded, observational, prospective, 1-year follow-up, controlled study to assess the efficacy of fingolimod (Gilenya) on remyelination and demelynation in patients with relapsing forms of multiple sclerosis.
    Novartis, Inc.
    Role: Principal Investigator
  • March 2013–December 2014
    a 36 months extension of multinational, multicenter, randomized, parallel-group study performed in subjects with RRMS to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg/ml administered three times a week or once we
    TEVA Pharmaceuticals, Inc.
    Role: Co-Principal Investigator
  • January 2013–December 2014
    Pediatric Imaging in multiple sclerosis
    The Annette Funicello Research Fund for Neurological Diseases
    Role: Principal Investigator
  • June 2012–December 2014
    A prospective, observational, single-blinded, longitudinal MRI study of the effect of glatiramer acetate on iron deposition in patients with relapsing-remitting multiple sclerosis over 24 months.
    TEVA Pharmaceuticals, Inc.
    Role: Principal Investigator
  • May 2012–December 2014
    A prospective, observational, single-blinded, longitudinal study of Natalizumab effect on brain atrophy and disability in multiple sclerosis patients over 5 years
    Biogen Idec, Inc.
    Role: Principal Investigator
  • January 2010–December 2014
    Magnetic resonance imaging (MRI testing of active implantable medical devices (AIMDs)
    Greatbatch Medical
    Role: Principal Investigator
  • December 2009–December 2014
    Natalizumab Temporary Discontinuation Study (NaTDS)
    Biogen Idec, Inc.
    Role: Principal Investigator
  • December 2009–December 2014
    Combined transcranial and extracranial venous Doppler evaluation (CTEVD study). Description of the design and interim results of an epidemiological study of the prevalence of chronic cerebrospinal venous insufficiency in MS and related diseases
    Direct MS Foundation, Jacquemin Foundation, Bronfman Foundation
    Role: Principal Investigator
  • December 2009–December 2014
    PREMiSe Trial: Prospective Randomized Endovascular therapy in Multiple Sclerosis
    Direct MS Foundation
    Role: Co-Principal Investigator
  • October 2008–December 2014
    Longitudinal analysis of regional brain atrophy and personality change in MS
    National Multiple Sclerosis Society
    Role: Co-Investigator
  • October 2008–December 2014
    BDNF in multiple sclerosis (Renewal).
    National Multiple Sclerosis Society
    Role: Co-Investigator
  • February 2009–June 2014
    Evolution of gray matter (GM) atrophy over 4 years in observational study of early interferon (IFN)β-1a intramuscular (I.M.) (Avonex® ) treatment in high risk subjects after clinically isolated syndrome (SET substudy)
    Biogen Idec, Inc.
    Role: Principal Investigator
  • July 2013–December 2013
    The efficacy of fingolimod (Gilenya) on the development of thalamus pathology and cognitive impairment in patients with relapsing forms of Multiple Sclerosis.
    Novartis, Inc.
    Role: Principal Investigator
  • March 2013–December 2013
    Additional post-hoc analyses in a multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Aetate (GA) injection 40
    TEVA Pharmaceuticals, Inc.
    Role: Principal Investigator
  • February 2012–December 2013
    Assessment of lesion activity analysis in the Avonex - Steroid - Azathioprine (ASA) study.
    Biogen Idec, Inc.
    Role: Principal Investigator
  • December 2009–December 2013
    A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg/ml administered three times
    Teva Pharmacuticals, Inc.
    Role: Principal Investigator
  • September 2010–September 2013
    Gene-Environmental Interactions in Progression of Multiple Sclerosis
    Department of Defense Multiple Sclerosis Research Program of the Office of the Congressionally Directed Medical Research Program
    Role: Co-Investigator
  • September 2009–December 2012
    A twenty-four week, two arm, pilot trial to evaluate remyelination/demyelination, gray matter volume and iron deposition in the central nervous system (CNS) and immune status of subjects with relapsing-remitting multiple sclerosis (RRMS) treated with Reb
    EMD Serono Inc.
    Role: Principal Investigator
  • January 2011–December 2011
    Neurology Lecture Series
    Teva Neuroscience, Inc.
    Role: Principal Investigator
  • January 2011–December 2011
    Interactive web-based continuing medical education (CME) program: Managing Parkinson's Disease: Diagnosis and Treatment Problems and Solutions
    Biogen Idec, Inc.
    Role: Principal Investigator
  • October 2010–December 2011
    Interactive web-based continuing medical education (CME) program: Understanding Multiple Sclerosis: Advances in Epidemiology, Pathology, Imaging and Treatment Strategies
    Teva Neuroscience, Inc.
    Role: Principal Investigator
  • June 2008–December 2010
    Quantitative progressive exercise rehabilitation for post-concussion syndrome.
    State University of New York at Buffalo
    Role: Co-Investigator
  • January 2008–December 2010
    Clinical and translational research in brain and behavior across the Lifespan.
    State University of New York at Buffalo
    Role: Co-Investigator
  • January 2006–December 2010
    Application for a pediatric multiple sclerosis center.
    National Multiple Sclerosis Society
    Role: Co-Investigator
  • December 2005–December 2010
    Neurological indices of CNS Involvement in Non-CNS SLE.
    National Institute of Health (NINDS)
    Role: Co-Investigator
  • January 2008–June 2010
    Assessment of a potential beneficial role of active CMV infection in MS models
    National Multiple Sclerosis Society
    Role: Consultant
  • June 2007–June 2010
    Perception and action in sequential behavior.
    National Science Foundation
    Role: Contributor
  • January 2007–December 2009
    Metabolic cerebral imaging in incipient dementia: Early and long-term value of imaging brain metabolism; A prospective, multi-center randomized study of the impace of regional cerebral metabolic assessment in patients undergoing evaluation for mold cogn
    National Institute of Health
    Role: Consultant
  • June 2004–June 2009
    Neurocognitive rehabilitation in alcohol treatment
    National Institute on Alcohol Abuse and Alcoholism
    Role: Contributor
  • January 2007–December 2008
    Multiple Sclerosis surveillance project.
    Agency for Toxic Substances and Disease Registry (ATSDR)
    Role: Principal Investigator
  • January 2007–December 2008
    Associations between post-traumatic stress symptoms and brain functioning in police officers.
    National Institute for Occupational Safety and Health
    Role: Contributor
  • June 2005–December 2008
    BDNF in Multiple Sclerosis
    National Multiple Sclerosis Society
    Role: Co-Investigator
  • January 2003–December 2008
    Advanced Approaches for the Integration and Analysis of Genomic Data.
    National Science Foundation
    Role: Co-Investigator
  • January 2007–December 2007
    Development of fully-automated software imaging program to provide quantified neuroimaging for stroke
    Jog for the Jake Foundation
    Role: Principal Investigator
  • June 2005–December 2007
    Predicting neuropsychological defects in MS with regional MTR using a semi-automated extraction technique
    National Multiple Sclerosis Society
    Role: Co-Principal Investigator
  • April 2002–March 2007
    A longitudinal study of mild cognitive impairment in multiple sclerosis
    SUNY Stony Brook
    Role: Consultant
  • January 2004–December 2004
    Estimation of State Transition Hazard Functions for a Standard Markov Model of Multiple Sclerosis.
    Duke University
    Role: Principal Investigator
  • August 1986–June 1989
    Macrophage imaging in patients with active secondary progressive Multiple Sclerosis
    National Multiple Sclerosis Society
    Role: Co-Investigator
See all (48 more)

Patents:

  • Intekrin Therapeutics, Inc.: (2019)

Journal Articles:

See all (431 more)

Abstracts:

  • Goldberg H, Weinstock A, Dwyer M, Bergsland N, Sazgar M, Poloni G, Zivadinov R. (2011) Automated Segmentation of Brain MRI for Quantification of Cortical and Subcortical Atrophy in Patients with Temporal Lobe Epilepsy. (Apr)
  • Zhang L, Dwyer M, Kerr S, Finnegan S, Zivanidov R, Weinstock A. (2004) Source Analysis of Interictal Sharp Waves in Focal Epilepsy. (Dec)

Professional Memberships:

  • American Neurological Association (2015–present)
  • European Academy of Neurology (2014–present)
  • International Society for Neurovascular Diseases (2011–present)
  • International Society for Magnetic Resonance Imaging (2005–present)
  • Italian Neurological Society (2004–present)
  • European Neurological Society (2004–present)
  • American Academy of Neurology (2003–present)
  • American Society of Neuroimaging (2003–present)
  • Croatian Society of Neurology (2001–present)
  • Italian Neurological Society of Triveneto (1997–present)

Presentations:

  • "Thalamic injury and cognition/fatigue in multiple sclerosis" 17th annual ARSEP (French MS society) MRI workshop - Thalamus & Multiple Sclerosis (CME) (2022)
  • "Detecting demyelination and remyelination by MRI in the CNS (CME; Course Director)" Consortium of Multiple Sclerosis Centers-Recovery and Repair: Remyelination and Clinical Trials (2021)
  • "Imaging biomarkers of disease progression in multiple sclerosis (CME)" 4th Rijeka Forum on neurodegenerative diseases-neurodegenerative diseases and COVID 19 Pandemic. (2020)
  • "Brain imaging research and neurological disease" Boldly Buffalo, The Campaign for UB (2018)
  • "Advances in imaging of multiple sclerosis" 3rd Annual Meeting, of Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS) (2018)
  • "Role of cardiovascular comorbidities in the pathogenesis of neurological disorders" 8th Annual International Society of Neurovascular Disorders (ISNVD) (2018)
  • "Is the central vein syndrome really helpful in differentiating MS from other white-matter disease – PRO (CME)" 12th World Congress of Controversies in Neurology (CONy) (2018)
  • "Progressive forms of MS respond to agents used for relapsing forms of the disease – CONS (CME)" 12th World Congress of Controversies in Neurology (CONy), (2018)
  • "Brain atrophy and predicting physical and cognitive disability in MS: Clinical relevance, the body of evidence and practical considerations (CME)" Sanofi-Genzyme Medical Meeting (2018)
  • "Brain atrophy and predicting physical and cognitive disability in MS: Clinical relevance, the body of evidence and practical considerations (CME)" Sanofi-Genzyme Medical Meeting (2018)
  • "Brain atrophy and predicting physical and cognitive disability in MS: Clinical relevance, the body of evidence and practical considerations (CME)" Sanofi-Genzyme Medical Meeting (2018)
  • "Watching the hourglass: disease monitoring and detecting disease activity in MS (CME)" Sanofi-Genzyme Medical Meeting (2018)
  • "A case-control, 5 year follow study of cardiovascular, environmental and genetic risk factors for disease progression in patients with MC (CEG-MS study) (CME)" 7th Annual International Society for Neurovascular Disorders (ISNVD) Meeting (2017)
  • "Effect of a cerebral protection device on brain lesions following TAVI in patients with severe aortic stenosis (CME)" 7th Annual International Society for Neurovascular Disorders (ISNVD) Meeting (2017)
  • "Brain atrophy should be used to guide therapy in multiple sclerosis: PRO (CME)" 11th World Congress of Controversies in Neurology (CONy) (2017)
  • "Leptomeningeal enhancement on MRI is a promising biomarker to monitor disease worsening, especially in progressive MS: PRO (CME)" 11th World Congress of Controversies in Neurology (CONy) (2017)
  • "Evaluation of Aubagio MRI efficiency" Academy of Knowledge, Scientific Exchange Forum (2017)
  • "Lemtrada outcome measures in the context of evolving treatment goals in MS" Academy of Knowledge, Scientific Exchange Forum (2017)
  • "Clinical relevance of brain atrophy in multiple sclerosis" 2nd MS Genzyme Summit (2017)
  • "Prognostic indicators of multiple sclerosis: Predicting disability" 2nd MS Genzyme Summit (2017)
  • "Evaluation of Aubagio MRI efficacy" Academy of Knowledge, Scientific Exchange Forum (2016)
  • "Preserving brain volume in multiple sclerosis." 14th PanAmerican Congress (2016)
  • "Susceptibility-weighted imaging and quantitative susceptibility mapping in the clinical trials of multiple sclerosis." 4th Workshop on MRI phase contrast & quantitative susceptibility mapping (QSM) (2016)
  • "A case-control, 5-year follow-up study of cardiovascular, environmental and genetic risk factors for disease progression in patients with MS (CEG-MS study)." 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
  • "Abnormal posture control of internal jugular vein flow is associated with brain atrophy progression in multiple sclerosis patients over 5 years." 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
  • "Cerebral microbleeds in multiple sclerosis. A case-control Study" 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
  • "Heart and brain in neurodegeneration: Venous prespective." 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
  • "Leptomeningeal contrast enhancement is associated with development of gray matter atrophy over 5 years in multiple sclerosis." 68th Annual Meeting of American Academy of Neurology; American Academy of Neurology (2016)
  • "Neurological Software Tool for Reliable Atrophy Measurement (NeuroSTREAM) in Multiple Sclerosis." 68th Annual Meeting of American Academy of Neurology; American Academy of Neurology (2016)
  • "Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis; The GALA study MRI and 36 month update" 8th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) Congress; PACTRIMS Congress (2015)
  • "No evidence of disease activity in treated patients after first clinical event suggestive of multiple sclerosis - follow-up study." Congress of the European Committee for Treatment and Research in Multiple Sclerosis,; ECTRIMS (2015)
  • "Cardiovascular risk factors and neurodegenerative disorders" 5th Annual Meeting of International Society for Neurovascular Disease; International Society for Neurovascular Disease (2015)
  • "Internal jugular vein cross-sectional area and cerebrospinal fluid pulsatility in the aqueduct of Sylvius" 5th Annual Meeting of International Society for Neurovascular Disease; International Society for Neurovascular Disease (2015)
  • "Prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis. Results of large cohort case-control ctudy." 5th Annual Meeting of International Society for Neurovascular Disease; International Society for Neurovascular Disease (2015)
  • "Biomarkers of neurodegeneration in multiple sclerosis." 7th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis; PACTRIMS Congress (2014)
  • "CLEAN-TAVI: A prospective, randomized trial of cerebral embolic protection in high-risk patients with aortic stenosis undergoing transcatheter aortic valve replacement." TCT Late Breaking News; TCT Late Breaking News (2014)
  • "Implications of DW-MRI and FLAIR signals from clinical Studies" TCT Claret Medical Satellite Symposium; Claret Medical (2014)
  • "Effect of terifllunomide (Aubagio) on gray matter pathology in Multiple Sclerosis: The 12 month, prospective, observational, single-blinded, longitudinal study" 2nd Genzyme Global Medical Summit; Genzyme (2014)
  • "Monotherapy of INT131 or placebo in the treatment of RRMS: Phase II trial design MRI specific study procedures" Protocol INT131-RU01-02 Investigator Meeting; Protocol INT131-RU01-02 Investigator Meeting (2014)
  • "Can we judge the efficacy of disease-modifying medications based on their effects on MRI brain atrophy?" The 8th World Congress on Controversies in Neurology; CONy (2014)
  • "Regeneration and remyleination are possible in MS lesions." The 8th World Congress on Controversies in Neurology; CONy (2014)
  • "CCSVI is associated with subcortical deep gray matter abnormalities in healthy individuals; A diffusion tensor MRI study." 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
  • "Identifying CCSVI with cervical plethysmography; TELEPASS study and Kosmomed project presentation." 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
  • "Inverse relationship between internal jugular vein narrowing and increased brain volumes in health individuals" 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
  • "Why we need a multi-modality diagnostic approach for CCSVI" 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
  • "Development of grey matter atrophy in relapsing remitting MS is not gender-dependent: results of a five-year follow-up study." 29th European Committee for Treatment and Research in MS; ECTRIMS; Multiple Sclerosis (2013)
  • "The role of noninvasive and invasive diagnostic imaging techniques for the detection of extracranial venous system anomalies and development variants (CME)" 2013 Annual Meeting of the Taiwan Stroke Society; Taiwan Stroke Society; Neurology (2013)
  • "Venous involvement in neurological disorders and aging (CME)" 2013 Annual Meeting of the Taiwan Stroke Society; Taiwan Stroke Society; Neurology (2013)
  • "The value of phase and susceptibility imaging in the study of multiple sclerosis, neurological diseases and aging." 2nd Workshop on MRI phase contrast & quantitative susceptibility mapping (QSM); Cornell University; Neuroradiology (2013)
  • "Assessing and managing neuropsychiatric problems in MS: From MRI to treatment (CME)" Consortium of MS Centers, Chicago, IL; Consortium of MS Centers; Neuropsychiatric - MRI (2013)
  • "A multinational, multicenter, randomized, placebo-controlled, double-blinded study to assess the efficacy, safety and tolerability of glatiramer acetate 40 mg injection three times per week in subjects with RRMS: efficacy and safety results of GALA study" 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2013)
  • "Cortical, thalamic- and subcortical grey matter atrophy as predictors of cognitive dysfunction in patients with multiple sclerosis: A 10-year follow-up study." 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2013)
  • "Gray matter pathology in multiple sclerosis: modern views on the role of thalamus and cortical atrophy (CME)." Michigan State University Resident Lecture; Michigan State University; MS (2013)
  • "Multimodal imaging manifestations of neuropsychiatric involvement in systemic lupus" 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Neuropsychiatry (2013)
  • "Thalamic atrophy is associated with the development of clinically definite MS" 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2013)
  • "Thalamus moves in MS spotlight (CME; GR)" SUNY Buffalo Department of Neurology - Grand Rounds Lecture; State University of New York at Buffalo; Multiple Sclerosis (2013)
  • "Changes of cine cerebrospinal fluid dynamics in multiple sclerosis patients treated with venous angioplasty" 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
  • "Chronic cerebrospinal venous insufficiency (CCSVI) in pediatric multiple sclerosis and other neurologic disorders." 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
  • "Chronic cerebrospinal venous insufficiency at ECTRIMS 2012." 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Venous Insufficiency (2013)
  • "Comparison of intravascular ultrasound (IVUS) to gold standard ctheter venography (CV) for the detection of extra-cranial venous abnormalities indicative of CCSVI: Results of the PREMiSe study" 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
  • "Multimodal diagnostic comparisons of 2 invasive and 2 non-invasive techniques in the Prospective Randomized Endovascular Treatment of MS PREMiSe study" 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
  • "The impact of chronic cerebrospinal venous insufficiency on intracranial physiology in healthy individuals." 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Chronic Venous Insufficiency (2013)
  • "A Phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40 mg administered 3 times a week compared to placebo." 28th European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2012)
  • "Relative contribution of thalamus volume and diffusion tensor metrics to cognitive impairment in multiple sclerosis." 28th European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2012)
  • "Cine cerebrospinal fluid imaging in multiple sclerosis and after endovascular treatment for CCSVI" 4th European Annual Meeting for minimal Invasive Surgery.; European Annual Meeting for minimal Invasive Surgery; Multiple Sclerosis (2012)
  • "Iron deposition in the subcortical deep-gray matter of pediatric multiple sclerosis patients" 64th American Academy of Neurology Annual Meeting; American Academy of Neurology; Multiple Sclerosis (2012)
  • "Subcortical deep gray matter SWI-filtered phase and atrophy are associated with disability in MS." 64th American Academy of Neurology Annual Meeting; American Academy of Neurology; Multiple Sclerosis (2012)
  • "Iron deposition and disability in Multiple Sclerosis" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2012)
  • "Iron deposition in clinically isolated syndrome" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
  • "Is CCSVI a disease?" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
  • "Morphological MRV multimodal studies in CCSVI" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
  • "MRI outcomes in multiple sclerosis" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2012)
  • "Perfusion changes in CCSVI" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
  • "Venous and CSF flow in brain parenchyma of MS patients" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2012)
  • "Venous involvement in neurological disorders" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
  • "Susceptibility-weighted imaging in neurological disorders" 35th Annual Meeting of the American Society of Neuroimaging; American Society of Neuroimaging; Neuroimaging (2012)
  • "Hypoperfusion of brain parenchyma in CCSVI" 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Neurology (2011)
  • "Intraluminal and extraluminal extra-cranial structural and functional venous abnormalities multiple sclerosis patients and healthy controls." 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Multiple Sclerosis (2011)
  • "Iron and veins in Multiple Sclerosis" 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Multiple Sclerosis (2011)
  • "The limits of magnetic resonance venography for the diagnosis of chronic cerebrospinal venous insufficiency" 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Neurology (2011)
  • "Hot topics in MS: Disease fundamentals and management of benefits and risks" The 5th Teva MS Experts Board Meeting (2010)
  • "Chronic cerebrospinal venous insufficiency: Relation to multiple sclerosis." 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2010)
  • "Presence and severity of Chronic Cerebrospinal Venous Insufficiency is related to lower brain parenchyma venous vasculature visibility on susceptibility-weighted imaging in patients with Multiple Sclerosis" 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2010)
  • "Chronic cerebrospinal venous insufficiency in Multiple Sclerosis" 62nd Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2010)
  • "Independent associtions of basal ganglia, thalamus and neocortical atrophy with slowed cognitive processing in multiple sclerosis" 63rd Annual Meeting of The American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2010)
  • "MRI measures in GALA study" GALA study (2010)
  • "Neurodegeneration and CNS repair in MS: MRI evidence (CME)" Advanced imaging techniques in MS (2010)
  • "Qualitative brain MRI features in children diagnosed with multiple sclerosis" 63rd Annual Meeting of The American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2010)
  • "Susceptibility-weighted imaging in neurological disorders" 62nd Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Neuroimaging (2010)
  • "Advanced imaging and chronic cerebrospinal venous insufficiency outcomes in multiple sclerosis" (2010)
  • "Advanced imaging in MS (CME)" Neurologic-Rhematologic Symposium (2010)
  • "Chronic cerebrospinal venous insufficiency and MRI outcomes in multiple sclerosis" CCSVI in MS (2010)
  • "Endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis; A longitudinal pilot study." 22nd Annual Meeting of American Venous Forum; The American Venous Forum; Multiple Sclerosis (2010)
  • "Chronic cerebrospinal venous insufficiency in multiple sclerosis" Intiture College of Neurology (2009)
  • "DMTs and MRI markers of neurodegeneration and CNS repair" Advanced imaging in MS (2009)
  • "Evidence for remyelination in Multiple Sclerosis" 23rd Slovakian Neurological Congress; Slovakian Neurological Congress; Multiple Sclerosis (2009)
  • "Neuroimaging of MS: State of the art and future directions." The Neuroradiology Education and Research Foundation; American Society of Neuroradiology; Neuroradiology (2009)
  • "Dirty appearing white matter on 1.5 and 3 tesla brain MRI in multiple sclerosis" 30th Congress of the Italian Neurological Society; Congress of The Italian Neurological Society; Multiple Sclerosis (2009)
  • "Advanced Imaging Techniques in Multiple Sclerosis: A Gaze into the Future" (2009)
  • "The Role of Gray Matter Damage in MS (CME)" Multiple Sclerosis & Parkinson Disease: Recent Developments & New Perspectives (2009)
  • "Advances in magnetic resonance imaging of multiple sclerosis (CME)" Annual Meeting of American Academy of Neurology, (2009)
  • "Advances in MS Neuroimaging (CME)" 12th Annual Review of Multiple Sclerosis & Parkinson's Disease, (2009)
  • "The role of gray matter pathology in MS (CME)" MRI and MS: From scientific to clinical routine evidence (2009)
  • "Multiple Sclerosis scientific topic highlights" 61st Annual Meeting of The American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2009)
  • "Sensitive and noise-resistant identification of voxel-wise changes in magnetization transfer ratio via cluster enhancement and M-estimator-based Monte Carlo simulation" 17th Annual ISMRM Meeting; ISMRM; Neuroimaging (2009)
  • "The role of gray matter pathology in MS (CME)" (2009)
  • "Gray matters: Impact of disease-modifying therapies and gray matter on the brain in MS patients (CME)" (2009)
  • "Practical Issues in Multiple Sclerosis: Imaging Concepts in MS (CME)" University of South Florida, Practical Issues in MS, Visiting Professors Series (2009)
  • "Neuroprotective effect of IM Inteferon-beta- 1a in MS: New evidences on brain atrophy." 29th Congress of Italian Neurological Society; Italian Neurological Society; Multiple Sclerosis (2008)
  • "Immunomodulation and neuroprotection: MRI perspectives." 24th Joint Annual Meeting of ECTRIMS, ACTRIMS and LACTRIMS; ECTRIMS, ACTRIMS and LACTRIMS; Neuroradiology (2008)
  • "New MRI advances in MS (CME; GR)" ; ; University of Missisipi, Department of Neurology, (2008)
  • "Using brain imaging to measure potential remyelination processes" The 2nd Teva Myelin Repair Meeting (2008)
  • "Long term effect of disease modifying therapies – New emerging MRI techniques in monitoring abnormalities and disability in MS" 5th LATAM (Latin America Multiple Sclerosi Meeting), (2008)
  • "Neuroprotection in MS as evidenced by MRI (CME; GR)" (2008)
  • "Using brain imaging to measure potential remyelination processes (CME; GR)" (2008)
  • "Can we measure remyelination with MRI in MS ? (CME; GR)" (2008)
  • "Advanced Imaging Techniques: New Management Strategies for Multiple Sclerosis and Parkinson’s Disease (CME)" (2008)
  • "Advanced MRI techniques in MS (CME; GR)" (2008)
  • "Demyelination and remyelination as evidenced by MRI in MS (CME; GR)" (2008)
  • "Update on MRI in MS (CME)" (2008)
  • "Is MRI a reliable tool for prediction of disability progression in patients with early relapsing-remitting multiple sclerosis?" European Charcot Foundation Symposium, 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, (2007)
  • "Role of MRI in imaging of myelin" 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, (2007)
  • "Extent of deep gray matter atrophy in patients with multiple sclerosis; A case control study." 17th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2007)
  • "Hippocampal volume does not correlate with memory impairment in Multiple Sclerosis" 17th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2007)
  • "Is MRI a reliable tool for the prediction of disability progression in patients with early relapsing-remitting multiple sclerosis? A 5-year longitudinal study." 17th meeting of the European Neurological Society; European Neurological Society; Neuroimaging (2007)
  • "Retinal nerve fiber layer thickness is associated with brain MRI outcome in multiple sclerosis patients." 21st Annual Meeting of the Consortium of Multiple Sclerosis Patients; Consortium of MS Centers; Multiple Sclerosis (2007)
  • "Severity of spinal cord atrophy is moderately related to severity of brain MRI measures in patients with MS" 17th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2007)
  • "Thle place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcomes (CME)" The 6th Teva and Sanofi-Aventis International Symposium on MS, Translating new insights on disease progression into treatment optimization in MS, (2007)
  • "Evidence for remyelination and regeneration by using MRI techniques in MS (CME; GR)" (2007)
  • "MRI and differential diagnosis of MS (CME)" (2007)
  • "Neuroprotection in Multiple Sclerosis: Can We Measure Neuroprotection & Remyelination With Imaging Techniques (CME; GR)" ; ; Department of Neurology, University of Hamilton (2007)
  • "Role of MRI in MS (CME)" ; ; Department of Neurology, University of Hamilton, (2007)
  • "Remyelination and neuroprotection as evidenced by MRI (CME)" (2007)
  • "Evidence for Neuroprotection in Multiple Sclerosis: Can We Measure Neuroprotection & Remyelination With Imaging Techniques (CME; GR)" (2007)
  • "Inflammation and Neurodegeneration in MS as Evidenced by MRI: Current Knowledge and Future Perspectives (CME)" (2006)
  • "Application of MRI in making diagnosis and prognosis of MS (CME; GR)" (2006)
  • "Efficacy results from a randomized, double-blinded, placebo-controlled study of intramuscular interferon beta - 1a, azatheoprince and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis." 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2006)
  • "MRI evidence for neuroprotection and remyelination (CME; GR)" (2006)
  • "Understanding of MS through MRI (CME)" (2006)
  • "MRI in pediatric MS" National Multiple Sclerosis Society meeting; (2006)
  • "Improving adherence and treatments outcomes in MS: A multifaceted challenge" Annual Meeting of the Consortium of Multiple Sclerosis Centers; ; Biogen Idec Inc. (2006)
  • "Inflammation and neurodegeneration in MS as Evidenced by MRI: Implications for current and future therapies" Annual Meeting of the Consortium of Multiple Sclerosis Centers; Teva Neuroscience Inc. (2006)
  • "MS management: Using history to guide the future" Annual Meeting of the Consortium of Multiple Sclerosis Centers; Teva Neuroscience Inc. (2006)
  • "The natural history of benign multiple sclerosis" Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of MS Centers; Multiple Sclerosis (2006)
  • "Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis." 16th meeting of the European Neurological Society; European Neurological Society; Neuroimaging (2006)
  • "Impact of spatial distribution of T2 and T1 lesion volume on processing speed in patients with multiple sclerosis" 16th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2006)
  • "Inflammation and neurodegeneration in MS: Evidence from MRI studies (CME: GR)" (2006)
  • "T1 intensity differences to normal appearing white matter in hypointense lesions on MRI are related to clinical status in multiple sclerosis." 16th meeting of the European Neurological Society; European Neurological Society; Neuroimaging (2006)
  • "Aging with MS and other neurodegenerative diseases (CME; GR)" (2006)
  • "Evolution of Benign Multiple Sclerosis in the New York State Multiple Sclerosis Consortium According to Different Classification Criteria" 58th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2006)
  • "Interferon Inhibitory Activities in Multiple Sclerosis Patients" 58th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2006)
  • "MRI in MS: Neurodegeneration and neuroprotection (CME; GR)" (2006)
  • "Multiple Sclerosis: Imuunological, genetic and clinical characteristics (CME; GR)" (2006)
  • "CNS atrophy in MS" Regional MS meeting: New frontiers in imaging (2006)
  • "MRI in MS: New MRI and immunological concepts (CME)" (2006)
  • "Pathogenesis of MS and MRI correlations" (2006)
  • "Rationale for diagnostic MRI criteria and new imaging techniques" Regional MS meeting: New frontiers in imaging, (2006)
  • "Role of emerging MRI techniques in MS (CME: GR)" (2006)
  • "Role of MRI in diagnosis and prognosis of MS: Rationale for early treatment" Regional MS Forum Middle East (2006)
  • "Inflammation and neurodegeneration as edvidenced by use of MRI (CME)" ; ; University of South Florida, Practical Issues in MS, Visiting Professors Series (2006)
  • "Corticosteroids in MS" NMSS Task Force meeting on role of steroids in MS (2005)
  • "MRI in MS: New concepts (CME)" (2005)
  • "Application of MRI in MS: What we learned in the last decade" National Multiple Sclerosis Society Annual Meeting (2005)
  • "Corticosteroid therapy in multiple sclerosis" University Classes in Multiple Sclerosis, European Charcot Foundation, (2005)
  • "Inflammation and neurodegeneration in MS: What lessons we learned in the last decade using MRI (JMC)" (2005)
  • "Controversis in neuropsychology of multiple sclerosis: Role of structural MRI in detecting cognitive impairment in patients with Multiple Sclerosis" Serono Symposia International (2005)
  • "Magnetic Resonance Imaging in MS: What we learned in the last decade (CME)" (2005)
  • "MRI as marker of neurodegeneration in MS (CME; GR)" (2005)
  • "Neuroimaging in multiple sclerosis: Nonconventinal MRI measure in MS (CME)" (2005)
  • "The meaning and application of MRI in MS (CME)" (2005)
  • "Utilizing MRI to diagnose and treat multiple sclerosis (CME; GR)" (2005)
  • "Evaluation of effect of disease-modifying treatment on conventional and nonconventional MRI measures (CME; GR)" (2005)
  • "Neurodegeneration and neuroprotection evaluated by different non-conventional MRI measures (JMC)" (2005)
  • "Pseudoatrophy and irreversible atrophy in MS" (2005)
  • "Quantitative analysis of lesion load progression in advanced multiple sclerosis" 21st Congress of the European Committee for the Treatment and Research in MS; ECTRIMS; Multiple Sclerosis (2005)
  • "Update on MRI in MS: New evidence for neurodegeneration" (2005)
  • "Use of MRI in multiple sclerosis" National Multiple Sclerosis Society (2005)
  • "Overview of Buffalo Neuroimaging Analysis Center MRI activities" (2005)
  • "Relation of cognitive dysfunction to multiple neuroimaging measures in multiple sclerosis over time" 57th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Neuroimaging (2005)
  • "New advances in managing MS - Magnetic resonance imaging in MS: Neurodegeneration and neuroprotection (CME)" (2005)
  • "Buffalo Neuroimaging Analysis Center database approach experience. A new model for magnetic resonance imaging and clinical and research studies (CME)" ; University of Cincinnati (2004)
  • "Magnetic resonance imaging in multiple sclerosis. Beyond enhancement and T2 (CME)" Thomas Jefferson University Neurology Resident CME Conference, (2004)
  • "Identifying disease modifying genes in multiple sclerosis. Clinical and MRI correlations" ; ; Harvard Medical School (2004)
  • "Application of MRI in multiple sclerosis and Assessment of treatment effect (CME)" (2004)
  • "Application of the non-conventional MRI in the sudy of MS" (2004)
  • "Long-term efficacy outcomes of diseasemodifying therapy in multiple sclerosis" Dompe’ Biotec Symposium 35th Congress of Italian Neurol. Society (2004)
  • "Steroid therapy and multiple sclerosis" ; ; Harvard Medical School (2004)
  • "Accuracy of segmentation with different brain atrophy techniques" 18th Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of Multiple Sclerosis Centers; Neuroimaging (2004)
  • "Application of global and regional MRI measures in the study of multiple sclerosis" (2004)
  • "Dompe’ Biotec Symposium 35th Congress of Italian Neurol. Society" ; ; Dept of Neurology, McGill University; (2004)
  • "Estimation of cerebral grey and white matter atrophy from various MRI pulse sequences" 18th Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of Multiple Sclerosis Centers; Multiple Sclerosis (2004)
  • "Evolution of confluent T2 lesions in relapsing-remitting multiple sclerosis" 18th Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of MS Centers; Multiple Sclerosis (2004)
  • "Global and regional MRI measures in the study of multiple sclerosis" ; ; Dept of Neurology, University of British Columbia; (2004)
  • "Bone mineral density in patients with relapsing-remitting multiple sclerosis treated with iv methylprednisolone pulses" 7th Congress of the European Society for Clinical Neuropharmacology; European Society for Clinical Neuropharmacology; Multiple Sclerosis (2004)
  • "Quality of life and side effects in patients with relapsing-remitting multiple sclerosis treated with interferon beta 1a" 7th Congress of the European Society for Clinical Neuropharmacology; European Society for Clinical Neuropharmacology; Multiple Sclerosis (2004)
  • "Regional-lobar or whole brain atrophy and clinical status in multiple sclerosis" 56th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2004)
  • "The Val66Met Polymorphism of Brain Derived Neurotrophic Factor is Associated with an Earlier Age of Disease Onset and more Destructive Brain MRI Pathology in MS Patients" 56th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2004)
  • "Application of Quantitative MRI in diagnosis and prognosis of multiple sclerosis (CME; GR)" (2004)
  • "Application of Quantitative MRI in diagnosis and prognosis of multiple sclerosis- Assessment of treatment effect (CME)" ; ; Department of Clinical Neurological Sciences, University of Western Ontario (2004)
  • "Effect of intravenous methyl-prednisolone on brain atrophy and confluent T2 lesions in relapsing-remitting multiple sclerosis" 9th European Charcot Foundation, (2003)
  • "Longitudinal study of MRI" 34th Congress of Italian Neurol. Society (2003)
  • "The evaluation of disease course by means of MRI" Scientific meeting on Multiple Sclerosis (2003)
  • "MMP-9 microsatellite polymorphism and multiple sclerosis" 13th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2003)
  • "Ring-Enhancement Pattern May Contribute to More Severe Disability Progression and Higher Disease Activity in the Short Term in Relapsing-Remitting MS" 55th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2003)
  • "Brain and spinal cord atrophy in multiple sclerosis" 26th Annual Meeting, American Society of Neuroimaging, New Orleans, (2003)
  • "A comparison of different quantitative MRI techniques to measure whole brain atrophy in relapsing-remitting multiple sclerosis" 32nd Congress of the Italian Neurological Society; Italian Neurological Society; Neuroimaging (2002)
  • "MMP-9 microsatellite polymorphism increases the risk of multiple sclerosis." 18th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; Americas Committee for the Treatment and Research in MS; Multiple Sclerosis (2002)
  • "Short-term brain atrophy changes in relapsing-remitting multiple sclerosis" Congress of the Italian Neurological Society; Italian Neurological Society; Multiple Sclerosis (2002)
  • "Gadolinium-enhancement and brain atrophy in multiple sclerosis" 12th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2002)
  • "Risk factors in Multiple Sclerosis" 12th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2002)
  • "MRI in MS: Use of new neuroimaging techniques in diagnosis, prognosis and in evaluation of the disease-modifying treatments efficacy" ; ; Farmades Meeting (2002)
  • "New Diagnostic Criteria for Multiple Sclerosis" 3rd Croatian Congress of Neurology, (2001)
  • "Sexual dysfunction in Multiple Sclerosis; An MRI, neurophysiological and urodynamic study" 32nd Congress of the Italian Neurological Society; Congress of The Italian Neurological Society; Multiple Sclerosis (2001)
  • "Standardized incidence and prevalence rates in epidemiological studies on MS" 32nd Congress of the Italian Neurological Society; Italian Neurological Society; Multiple Sclerosis (2001)
  • "A longitudinal study of the quality of life and its relationship with cerebral volume changes in chronic, progressive multiple sclerosis patients on therapy with interferon beta-1b" Investigator Meeting; Multiple Sclerosis Investigator Meeting; Multiple Sclerosis (2001)
  • "Long-term effects of intravenous methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis" 27th World Congress of Neurology; World Congress of Neurology; Multiple Sclerosis (2001)
  • "Managing the Adverse Effects in Multiple Sclerosis patients during Interferon beta-1b therapy" ; ; Farmades Meeting (2001)
  • "Migraine and tension-type headache in Croatia; a population-based survey of precipitating factors" 15th Congress of the National Society of Italy per lo Studio delle Cefalee; Congresso Nazionale Societa Italiana per lo Studio delle Cefalee; Neurology (2001)
  • "Quality of Life in Multiple Sclerosis Patients During Interferon beta-1b therapy" Farmades Meeting (2001)
  • "The use of standardized incidence and prevalence rates in epidemiological studies of Multiple Sclerosis is advisable." 11th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2001)
  • "A longitudinal study of brain atrophy and cognitive disturbances in early phase of relapsing-remitting multiple sclerosis." Autumnal meeting of Neurological Society of Triveneto; Neurological Society of Triveneto; Multiple Sclerosis (2000)
  • "A longitudinal study of brain atrophy and cognitive disturbances in early phase of relapsing-remitting multiple sclerosis" International Symposium on Multiple Sclerosis, (2000)
  • "Brain and spinal cord atrophy in multiple sclerosis: the new measures in clinical trials" Annual scientific meeting of Slovenian neurologists (2000)
  • "The use of NMR in diagnosing MS" European Medical Student’s Association (EMSA), 4th Croatian International Scientific Symposium, (2000)
  • "Olfactory dysfunction and extent of white matter abnormalities in Multiple Sclerosis; A clinical and MRI study." European Congress of Radiology; European Neurological Society; Multiple Sclerosis (2000)
  • "Value of different magnetic resonance imaging techniques in predicting the patterns of cognitive impairment in early phase of relapsing-remitting multiple sclerosis." European Congress of Radiology; European Congress of Radiology; Multiple Sclerosis (2000)
  • "Cerebral atrophy in multiple sclerosis: a new neuroradiological endpoint" Conference on MRI techniques in Multiple Sclerosis (1999)
  • "Incidence and prevalence of Myasthenia Gravis in the County of the Coast and Gorski Kotar, Croatia, 1976 through 1996" Annual scientific conference of the University of Rijeka, Croatia (1998)
  • "Assessing inflammation and neurodegeneration with MRI measures: Lessons from Multiple Sclerosis (JMC)"
  • "Can Imaging Techniques Measure Remyelination & Neuroprotection in MS ? (CME; GR)"
  • "Can we measure neuroprotection & remyelination with imaging techniques in multiple sclerosis (CME; GR)"
  • "Cerebral microbleeds in multiple sclerosis. A case-control Study" 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease
  • "MR non-conventional techniques and clinical correlates in MS (CME, GR)"
See all (223 more)

Service Activities:

  • ; Treasurer - International Society for Neurovascular Diseases (2021–2024)
  • Zivadinov R, Zamboni P, Ge Y, Wang M. Covid-19 and neurovascular complications. 1st International Society for Neurovascular Disease webinar meeting. June 24, 2020.; Chairman (2020)
  • ; Congressionally Directed Medical Research Development Programs (CDMRP) – Multiple Sclerosis Research (Chair of the Scientific Panel Committee) (2020–present)
  • Vice President of Research NSF Major Research Instrumentation Program 2020 Panel Committee Member; Panel Committee Member (2019–present)
  • Task Force on Safeguarding University and Faculty Assets and Interests Member; Task Force Member (2019–present)
  • Zivadinov R, Veroux PF, Pratesi C, De Bonis P. Headache and the Cerebral venous system. 9th Annual Meeting of the International Society for Neurovascular Disease, Ferrara, Italy, May 30, 2019:S5, p19.; Chairman (2019)
  • National Institute of Allergy and Autoimmune Disorders Congressionally Directed Medical Research Development Programs (CDMRP) – Neurological Research (Chair of the Scientific Panel Committee) (2018–present)
  • Ad Hoc Committee on Promotions to Academic (Tenurial) Ranks Member; Committee Member (2017–2020)
  • Mat Daemen, Zivadinov R. Imaging and mechanisms of neurodegeneration. 7th Annual Meeting of International Society for Neurovascular Disease. Naples, Italy, May 4-6, 2017.; Chairman (2017)
  • NIH Clinical Translational Science Institute Steering Committee Member; Committee Member (2017–present)
  • Directorship, Center for Biomedical Imaging, Clinical Translational Science Institute; Director (2017–present)
  • Zivadinov R, Mat Daemen. Heart & Brain Axis in Neurodegeneration. 6th Annual Meeting of International Society for Neurovascular Disease. New York City, NY, April 29-30, 2016.; Chairman (2016)
  • ; Swiss MS Research Foundation (2016–present)
  • Zivadinov R, Alexander S. Endothelial function, lymphatic system and new drug development. 5th Annual Meeting of International Society for Neurovascular Disease. Naples, Italy, March 27-28, 2015.; Chairman (2015)
  • ; Congressionally Directed Medical Research Programs (CDMRP) – Multiple Sclerosis Research (Scientific Reviewer) Belgium MS Research Foundation (2015–present)
  • Zivadinov R. A multi-modality diagnostic approach for extracranial venous disease. 4th Annual ISNVD Scientific Meeting, San Francisco, CA, February 8, 2014.; Chairman (2014)
  • ; Congressionally Directed Medical Research Programs (CDMRP) – Multiple Sclerosis Research (Scientific Reviewer) (2014–present)
  • Neuroscience PhD Program: Graduate faculty member; Graduate faculty member (2014–present)
  • Zivadinov R, Minagar A. S29: Neurologic Manifestations of Systemic Diseases. 65th American Academy of Neurology Annual Meeting, San Diego, CA, March 20, 2013.; Chairman (2013)
  • MRI Directorship, Center for Biomedical Imaging, Clinical Translational Science Institute; MRI Director (2013–2017)
  • ; Scientific member for neuroscience affairs in the Croatian Government (2013–2014)
  • ; Executive Director - International Society for Neurovascular Diseases (2013)
  • ; Dutch MS Research Foundation Physicians' Services Incorporated Foundation New Zealand MS Society The Research Foundation Flanders (2013–present)
  • Neuroscience PhD Program: Faculty member; Faculty member (2013–present)
  • ; Leadership Committee Member (2013–present)
  • Senate Committee on Social Affairs, Science and Technology: Public hearing on chronic cerebrospinal venous insufficiency (CCSVI). Invited testimony on CCSVI by Dr. Robert Zivadinov, Ottawa, Canada, Nov 1, 2012.; Committee Member (2012)
  • Zivadinov R, Minagar A. S08: Neurologic Manifestations of Systemic Diseases. 64th American Academy of Neurology Annual Meeting, New Orleans, LA, April 24, 2012.; Chairman (2012)
  • ; Medical Research Council Sheffield Hospital Charitable Fund (2012–present)
  • Zivadinov R, Luque F. S09: Neurologic Manifestations of Systemic Diseases. 63rd American Academy of Neurology Annual Meeting, Honolulu, HI, April 12, 2011.; Chairman (2011–present)
  • ; President - International Society for Neurovascular Diseases (2011)
  • ; Swiss National Science Foundation Netherlands Organization for Scientific Research (2011–present)
  • Zivadinov R, Rauchway AC. S47: Neurologic Manifestations: Clinical Neurophysiology and Epidemiology. 62nd American Academy of Neurology Annual Meeting, Toronto, CA, April 15, 2010; Chairman (2010–present)
  • ; Canadian Institute Health Research Austrian Science Fund Saskatchewan Health Research Foundation (2010–present)
  • BMC Neurol - Section Editor for demyelinating diseases; Editorial Director (2010–present)
  • ; Executive Committee Member - International Society for Neurovascular Diseases (2010–present)
  • President Elect - International Society for Neurovascular Diseases; President (2010–present)
  • Medical Research Council Grant Reviews; Reviewer (2010–present)
  • Austrian Science Foundation Grant Reviews; Reviewer (2010–present)
  • Sicotte N, Zivadinov R. Neuroimaging of MS: State of the art and future directions: What can properties of brain water (MTR, Myelin and DTI) tell? American Society of Neuroradiology: The Neuroradiology Education and Research Foundation, Washington DC, DC, Nov 7-8, 2009; Chairman (2009)
  • Schwendimann RN, Zivadinov R, Rauchway AC. S30: Neurologic Manifestations of Systemic Disease - Epidemiology. 61st Annual Meeting of American Academy of Neurology, Seattle, WA; Chairman (2009–present)
  • CTRC Imaging Committee; Committee Member (2009–present)
  • CTRC Translational Technologies and Resources Committee; Committee Member (2009–present)
  • Search Committee for Center for Brain and Behavior Informatics; Committee Member (2009–present)
  • ; CTRC Microstructural Animal MRI Committee (2009–present)
  • Neuroradiology; Genome Medicine; International Journal of MS Care; Journal of Cerebral Blood Flow; Magnetic Resonance in Medicine; Reviewer (2009–present)
  • Jog for the Jake Committee, Jacobs Neurological Institute, Department of Neurology, University of Buffalo, 2008-2011.; Committee Member (2008–2011)
  • Acta Neurologica Scandinavica; Human Brain Mapping; Journal of Neuroimflammation; Image and Vision Computing; CNS Spectrum Journal Reviews; Reviewer (2008–present)
  • Fondazione Italiana Sclerosi Multipla Grant Reviews; Reviewer (2008–present)
  • Sheffield Hospitals Charitable Trust Grant Reviews; Reviewer (2008–present)
  • Comi G, Zivadinov R. Is MRI a reliable tool for prediction of disability progression in patients with early relapsing-remitting multiple sclerosis? European Charcot Foundation Symposium, 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, (Check Republic); Chairman (2007–present)
  • Milonas I, Zivadinov R. Multiple Sclerosis 2. 17th meeting of European Neurological Society, Rhodos, Greece; Chairman (2007–present)
  • Human Brain Mapping Abstract Reviews; Reviewer (2007–present)
  • International Society for Magnetic Resonance Imaging Abstract Reviews; Reviewer (2007–present)
  • Multiple Sclerosis Scientific Research Foundation Grant Reviews; Reviewer (2007–present)
  • Expert Opinion in Neurology; Journal of Neuroinflammation; Future Medicine Journal Reviews; Reviewer (2007–present)
  • American Academy of Neurology Abstracts Review; Reviewer (2007–present)
  • Wellcome Trust Grant Reviews; Reviewer (2007–present)
  • New England Journal of Medicine; Journal of Pharmacy and Pharmacology; Journal of Interferon & Cytokine Research; BMC Neurology Journal Reviews; Reviewer (2007–present)
  • Multiple Sclerosis Journal Reviews; Reviewer (2006–present)
  • National Multiple Sclerosis Society Grant Reviews; Reviewer (2006–present)
  • Resident Advisory Committee; Committee Member (2005–present)
  • American Journal of Neuroradiology; Saudi Medical Journal, Medical Science Monitor; European Journal of Neurology; Neurology India Journal Reviews; Reviewer (2005–present)
  • Faculty Council; Councilor (2004–present)
  • Director of Resident Research Training SUNY at Buffalo, School of Medicine and Biomedical Sciences Department of Neurology/JNI; Director (2004–present)
  • Radiology; Journal of Neurological Sciences; Journal of Psychosomatic Research; Neuroimage; Brain; Archives of Neurology Journal Reviews; Reviewer (2004–present)
  • NeuroRX; Lancet Neurology; Annals of Neurology; Neurology; Journal of Neurology, Neurosurgery, Psychiatry Journal Reviews; Reviewer (2003–present)
  • Journal of Neuroimaging; Journal of American Medical Association; Drugs Journal Reviews; Reviewer (2001–present)
  • Veins and Lymphatics - Editorial board member
  • Word Journal of Surgical Procedures - Editorial board member
  • ; BioMed Res Int - Editorial board member
  • ; BMC Med - Editorial board member
  • Zivadinov R, Yiu Bai. Extracranial venous disease. 8th Annual Meeting of International Society for Neurovascular Disease. Naples, Italy, May 31-June 2, 2018.; Chairman
  • Zivadinov R, Reid D, Petrov I, Salvi F. Indication for CCSVI treatment. 9th Annual Meeting of the International Society for Neurovascular Disease, Ferrara, Italy, May 30, 2019:S4, p18.; Chairman
  • Zivadinov R. COVID-19: aerosol transmission, pathogenesis and vaccines: Pathogenesis and vaccines of COVID-19. 5th International Society for Neurovascular Disease webinar meeting. March 4, 2021.; Chairman
  • ; Clinical CNS Drugs - Editorial board member
  • Jog for Jake Committee Jacobs Neurological Institute; Committee Member
  • ; Conference Papers in Neuroscience - Editorial board member
  • ; Journal of Alzheimer's Disease - Associate Editor
  • ; Neurovascular Imaging - Editorial board member
  • ; Quantitative Imaging in Medicine and Surgery- Editorial board member
  • ; Translational Neuroscience - Editorial board member

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

Buffalo Neuroimaging Analysis Center
D-2 Buffalo General Hospital
100 High St
Buffalo, New York 14203
Phone: (716) 859-7040
Fax: (716) 859-7066
rz4@buffalo.edu